I think that discovery will show that NWBO is roughly as secretive about all that it's doing as most biotech's are. Shareholders always believe that they're entitled to know more than they do, but I believe that all information that they're mandated to provide to investors has been provided. No doubt they'll see that Clinical Trials should have previously been updated, but they'll also see that the U.K. and European versions had clearly been updated many months prior.
I'm not suggesting the company's been perfect, they haven't, but neither are most other biotech's. For all we know submissions were made in a timely way to the NIH but the regulator took more time than guidance would indicate they need. Companies never like to criticize what the regulators do, so even if they could, they'll take the blame rather than passing it on. In discovery they would probably show that they filed in time, if that was the case, but that won't be shared with investors unless the law requires it.
The record will certainly show that NWBO didn't try to hype the share price in any way, they were depending on the facts to support where the share price should be. AdamF certainly did his best to bring the price down especially after he learned that Dr. Liau had Covid 19 in the U.K. and couldn't make the NYAS presentation, he even suggested she wasn't sick at all, just didn't want to make the presentation because in his opinion she didn't see it as a success. Was AdamF a tool of the spoofers, sure, they knew they could count on him to be negative, but Dr. Liau getting Covid was an added bonus and both used it to the best of their abilities.
Gary
Bullish
AI
Market Data 
Markets 
